MedTrace Logo

Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

NCT01639131 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-08-10

Study results available
· View outcomes & findings →

Summary

The primary goal of the trail was to determine the efficacy of combining Gemcitabine and Docetaxel in treatment of metastatic colorectal cancer with CHFR and/or Microsatellite Instability (MSI) phenotype.

Conditions

  • Metastatic Colorectal Adenocarcinoma

Interventions

DRUG

Gemcitabine

intravenous gemcitabine 800mg/m2 on days 1 and 8

DRUG

Docetaxel

intravenous docetaxel 70mg/m2 on day 8 of each 21 day cycle

DRUG

Filgrastim or Pegfilgrastim

filgrastim (granulocyte colony-stimulating factor \[G-CSF\]) on days 9 through 15 or pegfilgrastim 6 mg on day 9 or 10 of each cycle

Sponsors & Collaborators

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    lead OTHER

Principal Investigators

  • Nilofer Azad · SKCCC at JHMI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-10
Primary Completion
2016-10-03
Completion
2019-03-11

Countries

  • United States
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639131 on ClinicalTrials.gov